Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706721 | 0.84 | TSHR (0.50) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL6249203 | 0.83 | TSHR (0.58) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL16042478 | 0.83 | TSHR (0.58) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL7653479 | 0.82 | TSHR (0.48) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL7650726 | 0.81 | TSHR (0.47) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL29489290 | 0.81 | TSHR (0.56) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| Potassium SCHEMBL29978462 | 0.81 | TSHR (0.56) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL607362 | 0.81 | CYP1A2 (0.56) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL29489289 | 0.81 | TSHR (0.56) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 | |
| SCHEMBL7655585 | 0.80 | TSHR (0.46) | TSHRCYP1A2CYP2A6ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289710-B1 | Pneumatic tire | BRIDGESTONE CORP (JP) | 2018-11-07 | — | — | EP | disclosed |
| EP-1297974-B1 | PNEUMATIC TIRE | BRIDGESTONE CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-8183327-B2 | Rubber composition for tire and pneumatic tire | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110306579-A1 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| US-8058357-B2 | Vulcanizable compositions and tire treads prepared therewith | BRIDGESTONE CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110071253-A1 | RUBBER COMPOSITION FOR TIRE AND PNEUMATIC TIRE | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2289710-A2 | Pneumatic tire | Bridgestone Corporation (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-2287015-A2 | Pneumatic tire | Bridgestone Corporation (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1197518-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE MADE WITH THE SAME | BRIDGESTONE CORPORATION (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1172430-A2 | Lubricant composition for steel filament and rubber-steel filament composite body | Bridgestone Corporation (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| CN-1293674-A | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | TORAY INDUSTRIES (JP) | 2001-05-02 | — | — | CN | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306579-A1 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D | CYP27B1, GAP43, VDR | TSHR 2579/4885CYP1A2 3362/4885CYP2A6 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.